Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Bixin WangDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.ORCID 0009-0000-9613-2734
Xu CaoDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Krystine Garcia-MansfieldCancer and Cell Biology Division, Translational Genomics Institute, Phoenix, AZ 85004, USA.ORCID 0000-0002-9089-2254
Jingkai ZhouDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.ORCID 0000-0002-9867-3486
Antigoni ManousopoulouDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Patrick PirrotteCancer and Cell Biology Division, Translational Genomics Institute, Phoenix, AZ 85004, USA.
Yingyu WangCenter for Informatics, City of Hope, Duarte, CA 91010, USA.
Leo D WangDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.ORCID 0000-0002-2945-9005
Mingye FengDepartment of Immuno-Oncology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA.
Funding
Targeting tumor-associated macrophages for triple-negative breast cancer treatmentR01CA258778 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2023 to 2025
$1.5M
Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancerR01CA255250 · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2025 to 2025
$432k
Non-receptor protein tyrosine phosphatases in macrophage-mediated cancer cell phagocytosis.R21CA280317 · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2025 to 2025
$250k
California Institute for Regenerative Medicine CLIN2-12153California Institute for Regenerative Medicine INFR4-13587Marcus Foundation Marcus FoundationNCI NIH HHS R01 CA255250NCI NIH HHS R01 CA258778NCI NIH HHS R21 CA280317NIH HHS R01CA255250NIH HHS R01CA258778NIH HHS R21CA280317Pediatric Cancer Research Foundation Pediatric Cancer Research FoundationV Foundation for Cancer Research Pediatric translational award
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
cancer immunotherapymacrophagemTORphosphoproteomics
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Phosphoproteomic Profiling Reveals mTOR Signaling in Sustaining Macrophage Phagocytosis of Cancer Cells. · full record | Socratic